Neonatal Diabetes Mellitus Caused by Activation Mutation in the Gene
Encoding the Kir6.2 Subunit of Potassium Channel: Is Insulindependency
Inevitably Life-long?
Šumník Z.1, Průhová Š.2, Koloušková S.1, Cinek O.1, Lebl J.2, Vavřinec J.1, Hattersley A. T.3
Pediatrická klinika 2. LF UK a FN Motol, Praha1 přednosta prof. MUDr. J. Vavřinec, CSc. Klinika dětí a dorostu 3. LF UK a FN Královské Vinohrady, Praha2 přednosta prof. MUDr. J. Lebl, CSc. Institute of Biomedical and Clinical Science, Peninsula Medical School, Exeter, Velká Británie3 |
|
Summary:
Introduction: Permanent neonatal diabetes mellitus (PNDM) is a rare disorder of heterogeneous
aetiology. Activating mutations in the KCNJ11 gene encoding the Kir6.2 subunit of ATPsensitive
potassium channel were recently described as one of the causes of PNDM. As KCNJ11 is
expressed in muscle, brain and heart as well as beta-cells there could be diverse phenotypic
expressions. Some patients with KCNJ11 mutations have no extra-pancreatic features and respond
to sulphonylureas.
Patients: Authors present three cases with PNDM caused by the heterozygous mutations in
KCNJ11: R201H, V59G and Q52R. The child with R201H mutation is characterized by normal psychomotor
development and normal phenotype. The other two cases suffer from very similar neurological
symptoms: apart from insulin-dependent PNDM and low birth weight, all had a marked developmental delay, muscle weakness and epilepsy, which did not result from diabetes and/or
its treatment. Their physical appearance is characterized by down turned mouth, bilateral ptosis
and limb contractures. The patient with the most severe motor delay (Q52R) died at the age of 1.2
year. The patient with PNDM caused by R201H mutation did secrete insulin in response to
sulphonylurea and he can discontinue insulin. Authors observed no change either in insulin
requirement, diabetes control or neurological/developmental status 12 months after adding
sulphonylurea to insulin therapy in subject with neurological symptoms carying V59G.
Conclusion: In conclusion, a subgroup of subjects can be differentiated among patients with
PNDM caused by activating mutations in the KCNJ11 gene, which respond to sulphonylurea treatment.
The patients with KCNJ11 mutations and neurological symptoms may represent functionally
more severe activating mutations of KCNJ11 that do not respond to sulphonylureas
Key words:
permanent neonatal diabetes mellitus, Kir6.2, sulphonylurea
|